Accord BioPharma Expands Its U.S. Biosimilar Portfolio with UDENYCA Acquisition

Accord BioPharma Expands U.S. Biosimilar Portfolio through UDENYCA Acquisition

Introduction

Accord BioPharma, Inc., part of Intas Pharmaceuticals, has successfully completed the acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc. This significant milestone in April 2025 marks a substantial enhancement to Accord’s biosimilar portfolio, reinforcing its resolve to broaden access to vital therapies in the oncology and immunology sectors.

The Relevance of UDENYCA

UDENYCA is a biosimilar to Neulasta® (pegfilgrastim), primarily indicated for decreasing infection rates in patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments. This acquisition will ensure that patients continue to benefit from this critical therapy, especially when they face the risk of febrile neutropenia. UDENYCA offers three flexible delivery options: the autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS), allowing patients to receive treatment at home or in healthcare facilities as needed.

Market Impact

By adding UDENYCA to its offerings, Accord BioPharma continued to assert itself as a player in the burgeoning biosimilar arena, responding to the growing demand for effective and affordable biologics. Since its market introduction, over 300,000 patients have reportedly been treated with UDENYCA, showcasing the significant clinical need for such therapies. This move not only enhances Accord's product range but also bolsters its competitive edge in the U.S. market.

Team Expansion

Alongside this acquisition, Accord welcomes a wealth of talent from Coherus BioSciences. Key personnel across sales, marketing, finance, supply chain, and quality control functions will join Accord, facilitating a smooth transition in operations and further enhancing the organization’s capabilities.

Leadership Insights

Chrys Kokino, U.S. President of Accord, expressed enthusiasm about this acquisition. He noted, "The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities in biosimilars." He emphasized the value of integrating Coherus employees into the Accord team, highlighting their expertise in driving future successes with UDENYCA.

Additionally, Binish Chudgar, Executive Chairman of Intas Pharmaceuticals, emphasized the strategic importance of this acquisition in improving patient access to high-quality biologic treatments. He stated, "We are delighted to add the UDENYCA product to our portfolio because it showcases our commitment to addressing patient needs effectively."

Future Directions

Accord BioPharma’s acquisition of UDENYCA not only solidifies its standing in the biosimilar market but also aligns with its mission to deliver affordable, patient-centered therapies in oncology and immunology. With this expanded portfolio, Accord is well-positioned to meet the evolving demands of healthcare providers and patients alike.

Conclusion

The acquisition of UDENYCA represents a major leap forward for Accord BioPharma in enhancing its product offerings while reaffirming its commitment to patient care and innovation within the biosimilar arena. As the market for biosimilars continues to grow, Accord remains dedicated to broadening access to essential therapies, ensuring that patients receive the best available treatment options.